New triple therapy aims to tackle tough leukemia mutation
NCT ID NCT06561880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with acute myeloid leukemia (AML) who have a specific genetic change called FLT3 mutation. The goal is to see if this triple therapy can improve remission rates and survival. About 66 participants aged 15 and older will receive the treatment, and researchers will monitor side effects and outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can pressurized oxygen boost cord blood transplants?
- Personalized leukemia vaccine aims to outsmart relapse
- Supercharged donor cells aim to stop leukemia return after transplant